STOK insider transactions
Stoke Therapeutics Inc. (STOK) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
STOK insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Stoke Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Barry TichoChief Medical Officer-$6.98M
- Jonathan AllanGeneral Counsel & Corp Sec, since March 2023-$2.84M
- Alexander CumboDirector, since September 2026
- Kaye Edward M. MDCEO, Director-$5.7M
- Seth Loring HarrisonDirector
- Thomas McCauleyChief Scientific Officer, since July 2026
- Arthur TzianabosInterim Executive Chair, Director-$781K
- Julie SmithDirector
- Arthur A LevinDirector-$782K
- Adrian R. KrainerDirector-$3.9M
- Jennifer BursteinDirector
- Clare KahnDirector, since April 2026
- Thomas LeggettChief Financial Officer, since May 2024-$147K
- Jason HoittChief Patient Officer, since June 2025-$119K
- Ian F SmithChief Executive Officer, Director, since September 2023
- Skorpios Trust10% owner, since June 2021-$123M
- Garry E MenzelDirector, since August 2020
- Huw M. NashChief Business Officer-$2.67M
- Stephen J TulipanoFormer CFO-$1.79M
- ATP Life Science Ventures, L.P.10% owner
- Gene LiauOfficer-$336K
Recent Form 3, 4, and 5 filings for STOK
- CHIEF MEDICAL OFFICER Ticho Barry sold $189,912 worth of shares (7,195 units at $26.39) as part of a pre-agreed trading plan, decreasing direct ownership by 38% to 11,864 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $16,509 worth of shares (627 units at $26.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 20,598 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $27,494 worth of shares (1,051 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 19,059 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Stoke Therapeutics Inc.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 3 filed by new insider Cumbo Alexander3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $170,061 worth of shares (5,545 units at $30.67) as part of a pre-agreed trading plan, decreasing direct ownership by 22% to 20,110 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $152,690 worth of shares (4,767 units at $32.03), increasing direct ownership by 26% to 25,655 units (SEC Form 4) to satisfy withholding tax4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $91,639 worth of shares (2,861 units at $32.03), increasing direct ownership by 17% to 21,225 units (SEC Form 4) (tax withholding)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $208,385 worth of shares (7,176 units at $29.04) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 20,422 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Mccauley Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 3 filed by new insider Mccauley Thomas3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $236,068 worth of shares (7,228 units at $32.66) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 27,598 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $43,637 worth of shares (1,457 units at $29.95) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 18,086 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Tzianabos Arthur4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Smith Julie4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Levin Arthur A4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Krainer Adrian R.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Kaye Edward M. Md4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Burstein Jennifer4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $54,891 worth of shares (1,795 units at $30.58) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 34,826 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $73,548 worth of shares (2,243 units at $32.79) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,621 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Kahn Clare4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 3 filed by new insider Kahn Clare3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Leggett Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Hoitt Jason4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Chief Patient Officer Hoitt Jason converted options into 10,000 shares, increasing direct ownership by 251% to 13,988 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Chief Financial Officer Leggett Thomas converted options into 14,750 shares (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 33,850 shares, increasing direct ownership by 171% to 53,648 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 61,750 shares, increasing direct ownership by 126% to 110,874 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 25,475 shares, increasing direct ownership by 208% to 37,731 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A sold $22,264 worth of shares (605 units at $36.80), decreasing direct ownership by 12% to 4,237 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Interim Executive Chair Tzianabos Arthur exercised 3,955 shares at a strike of $8.33 and sold $174,214 worth of shares (4,355 units at $40.00), decreasing direct ownership by 1% to 31,339 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,320,964 worth of shares (33,243 units at $39.74), decreasing direct ownership by 11% to 283,302 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $286,715 worth of shares (7,229 units at $39.66), decreasing direct ownership by 2% to 316,545 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by CHIEF MEDICAL OFFICER Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Smith Ian F4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Leggett Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Patient Officer Hoitt Jason4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by GENERAL COUNSEL & CORP SEC Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A converted options into 1,211 shares, increasing direct ownership by 33% to 4,842 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $128,411 worth of shares (3,978 units at $32.28), decreasing direct ownership by 25% to 11,831 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $433,385 worth of shares (13,430 units at $32.27), decreasing direct ownership by 21% to 49,124 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $167,115 worth of shares (5,358 units at $31.19), increasing direct ownership by 31% to 19,798 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 26,250 shares and sold $466,959 worth of shares (15,001 units at $31.13), increasing direct ownership by 22% to 62,554 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $306,322 worth of shares (9,803 units at $31.25), decreasing direct ownership by 19% to 15,809 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 11,981 shares and sold $121,468 worth of shares (4,020 units at $30.22), increasing direct ownership by 111% to 15,156 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $64,541 worth of shares (2,136 units at $30.22) and converted options into 4,317 shares, increasing direct ownership by 4% to 51,305 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $138,268 worth of shares (4,576 units at $30.22) and converted options into 12,357 shares, increasing direct ownership by 66% to 19,612 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,202,719 worth of shares (40,472 units at $29.72), decreasing direct ownership by 11% to 323,774 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,092,058 worth of shares (40,472 units at $26.98), decreasing direct ownership by 10% to 364,246 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $152,566 worth of shares (5,931 units at $25.72), decreasing direct ownership by 45% to 7,195 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Smith Ian F4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $750,000 worth of shares (25,000 units at $30.00) and exercised 25,000 shares at a strike of $0.60 (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)